You just read:

In a Phase 3 Trial, NovoEight® Provided Long-term Efficacy and Safety in the Prophylaxis and Treatment of Bleeds in People with Haemophilia A

News provided by

Novo Nordisk

24 Jun, 2015, 12:30 BST